CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a significant milestone in the global development...
Hence then, the article about cstone announces fda clearance of ind application for its novel trispecific antibody cs2009 pd 1 vegf ctla 4 to advance into phase ii clinical trial was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial )
Also on site :
- Police: Two killed in shooting at West San Jose shopping center
- OpenAI COO says ‘we have not yet really seen AI penetrate enterprise business processes’
- Judge Rules That ICE Agents Violate the Fourth Amendment by Making Arrests While Masked